美国基因与细胞治疗学会：2025年第二季度基因、细胞与RNA疗法概览报告（英文版）

Welcome to 2025’s second quarterly report from ASGCT, Citeline, and Evaluate! This past quarter, three new therapeutics were approved, and the number of gene therapy programs continues to climb. In the US, FDA approved the cell-based gene therapy Zevaskyn for recessive dystrophic epidermolysis bullosa (RDEB) as well as the lower-dose mRNA vaccine mNexspike for COVID-19. In China, the country’s first gene therapy for hemophilia B was approved. Gene therapy programs at each stage from preclinic